Vaccine for children and teens with low-grade brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a peptide vaccine plus a medication called poly-ICLC for people with certain low-grade gliomas that cannot be fully removed. The goal is to help the immune system recognize and attack the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have an unresectable low-grade glioma that has had at least two prior chemotherapy or biologic treatments (radiation can count as a biologic), and the tumor may have spread within the brain/spinal cord
- Be HLA-A2 positive on a blood test (flow cytometry)
- Be between 12 months old and under 22 years old at the time of screening
- Be able to do daily activities at a good level (performance status at least 70 on the study scale) and be off high-dose anti-inflammatory steroid medicines for at least 1 week
- Have no active serious infection that needs IV antibiotics right now, and be off IV antibiotics for at least 7 days before enrolling
- Have enough healthy blood and organ function (blood counts, liver tests, and kidney function) and have recovered from prior treatment side effects to mild level (grade 1 or better)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a laser treatment called LITT for low-grade glioma (a type of brain tumor) that has come back or is growing despite prior treatment. It aims to see if the laser is safe and effective in young people aged 2 to 25.
This trial tests a vaccine that may help the immune system fight brain tumors (medulloblastoma, high-grade glioma, and DIPG). It is for patients who have already had standard treatment and whose tumors are still present or have returned.
This Phase 1 study tests vorasidenib combined with a personalized tumor-targeting peptide vaccine in adults with a specific type of recurrent brain tumor. It aims to see how safe the combination is and whether it can help slow the tumor’s growth.
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
This trial tests an experimental vaccine for glioblastoma, given after the usual radiation and chemotherapy (temozolomide). The goal is to see if the vaccine helps the immune system fight remaining cancer cells.
This trial tests a new mRNA vaccine for people with a type of brain tumor called high-grade glioma that has come back or progressed. The vaccine is designed to help your immune system recognize and attack the tumor cells.
Hear when a new Low-grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.